Skip navigation

PredictImmune Join the Babraham Research Campus Community

14 May 2018

Babraham, 14th May 2018: The Babraham Research Campus is pleased to welcome PredictImmune to the Campus community.  

PredictImmune is developing pioneering tools to guide physicians in the treatment of patients with immune-mediated disease, through prediction of long-term clinical prognosis. The company is currently developing its first product, a prognostic biomarker test, to address inflammatory bowel disease (both Crohn’s and ulcerative colitis).  This technology, which is based on world-leading research emanating from the University of Cambridge, accurately identifies patients -  at diagnosis - who are at risk of experiencing severe, relapsing disease and therefore likely to benefit from early biologics therapy. 

The company recently secured an additional £4.3m investment from the Wellcome Trust to support a prospective multi-centre clinical trial of the prognostic biomarker test, having raised £4.7m Series A funding in May 2017 led by Parkwalk Opportunities Fund with co-investment from Cambridge Enterprise and Wren Capital.

Andrew Sandham, Executive Chairman, PredictImmune

said: “We are pleased to have secured high quality laboratory and office space at the Babraham Research Campus as we continue to expand our operations, in advance of launching our first diagnostic test for IBD.  The Campus provides an extremely supportive hub for biotechnology companies to build from start-up to commercialisation, with excellent proximity to clinical and academic collaborators and strong business networking.”

The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, creating an environment where world class research and business come together to promote innovation and strengthen links between academia and the commercial world.  The Campus is specifically focused on creating a vibrant and supportive eco-system where companies can focus on developing their science and building their business within a highly nurturing and networked community - helping to create new medicines, jobs and growth, and thereby maximising the impact of UK science.

Having taken laboratory space within the Maia Building, PredictImmune join a community of over 60 commercial companies already located on Campus, which includes Bicycle Therapeutics, Crescendo Biologics, Kymab and RxCelerate.  

Derek Jones, CEO, Babraham Bioscience Technologies commented:

“I’m delighted that PredictImmune has decided to locate here and particularly pleased to welcome Andy Sandham back to the Campus in his role as PredictImmune’s Executive Chairman.  The fact that we see serial entrepreneurs returning time and again is a fantastic endorsement of the Babraham Research Campus as a great environment from which to start and grow a life science business. Our focus on community, capability and connectivity has enabled us to develop a campus community that is one of the best places in Europe to start-up and grow a life science venture and as such attracts organisations, like PredictImmune, which are based on the best of global scientific discoveries, often generated in the universities and research institutes in our region.”


Derek Jones, CEO, Babraham Bioscience Technologies
Tel: 01223 496262

Sarah Brereton, Director, Limewash
Tel: 01223 813 560

Notes to Editors

About Babraham Research Campus

Babraham Bioscience Technologies Ltd (BBT) is responsible for the management and commercial development of the Babraham Research Campus. 

The Babraham Research Campus is distinct in its co‐location of 60 bioscience companies with the Babraham Institute, a world‐renowned research organization which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC). 

The aim of the campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organizations. The campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster. 
The campus is managed and developed by BBT on behalf of the BBT shareholders, BBSRC and the Babraham Institute. For more information please visit:

About PredictImmune

PredictImmune aims to develop and commercialise a series of biomarker tests to guide physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.   The first such test, for inflammatory bowel diseases, was discovered and developed in the laboratory of Professor Kenneth Smith, Head of the Department of Medicine at the University of Cambridge in collaboration with gastroenterologists at Cambridge University Hospitals NHS Foundation Trust and other UK NHS hospital trusts.  His group has published on the underlying biology of the prognostic biomarkers that comprise the test, which also have relevance in other inflammatory and autoimmune diseases, including vasculitis and Lupus (SLE), where clinical research and development is ongoing in the Smith laboratory.  Independent market research indicates that physicians, patients and payers will recognise the value of personalised treatment guidance in Crohn’s disease and ulcerative colitis.  The company is currently progressing its Crohn’s Disease prognostic test towards CE mark registration within the European regulatory process and is engaging with payers to model potential health-economic impact.